NCT Number |
Title |
Conditions |
Interventions |
Sponsor/Collaborators |
Phases |
NCT03290248 |
Study to Assess the Safety, Tolerability, and Preliminary Efficacy of B244 in Healthy Volunteers and Subjects With Seasonal Allergic Rhinitis |
Allergic Rhinitis|Allergic Rhinitis Due to Grass Pollen|Healthy Volunteers |
Biological: B244 suspension|Biological: Vehicle |
AOBiome LLC|Orange County Research Center|Integrium |
Phase 1
Phase 2 |
NCT03290937 |
Clinical Trial Evaluating the Safety and Response With PF-05082566, Cetuximab and Irinotecan in Patients With Advanced Colorectal Cancer |
Malignant Neoplasms of Digestive Organs|Colorectal Cancer |
Drug: Irinotecan
Drug:PF-05082566
Drug: Cetuximab |
M.D. Anderson Cancer Center|Pfizer |
Phase 1 |
NCT03290664 |
CD3-/CD19- vs CD3-/CD56+ Haplo NK for AML Pts Who Failed 1-2 Inductions |
Acute Myelogenous Leukemia |
Biological: CD3-/CD19-|Biological: CD3-/CD56+ |
Masonic Cancer Center, University of Minnesota|Miltenyi Biotec, Inc. |
Phase 2 |
NCT03290079 |
Pembrolizumab in Advanced Poorly Differentiated and/or High Grade Neuroendocrine Tumors/Carcinomas |
Neuroendocrine Tumors|Neuroendocrine Carcinoma|Neuroendocrine Cancer |
Drug: Pembrolizumab |
H. Lee Moffitt Cancer
Center and Research Institute|Merck Sharp & Dohme Corp. |
Phase 2 |
NCT03291054 |
Epacadostat and Pembrolizumab in Patients With GIST |
Gastrointestinal Stromal Tumors |
Drug: Pembrolizumab|Drug: Epacadostat |
Richard D. Carvajal|Columbia University |
Phase 2 |
NCT03288493 |
P-BCMA-101 Tscm CAR-T Cells in the Treatment of Patients With Multiple Myeloma (MM) |
Multiple Myeloma |
Biological: P-BCMA-101 CAR-T cells |
Poseida Therapeutics, Inc. |
Phase 1 |
NCT03292172 |
A Study to Evaluate the Safety, Pharmacokinetics and Clinical Activity of RO6870810 and Atezolizumab (PD-L1 Antibody) in Participants With Advanced Ovarian Cancer or Triple Negative Breast Cancer |
Advanced Ovarian Cancer|Triple Negative Breast Cancer |
Drug: Atezolizumab|Drug: RO6870810 |
Hoffmann-La Roche |
Phase 1 |
NCT03290950 |
A Study of Daratumumab in Patients With Newly Diagnosed Multiple Myeloma |
Multiple Myeloma |
Drug: daratumumab|Drug: carfilzomib|Drug: lenalidomide|Drug: dexamethasone |
Memorial Sloan Kettering Cancer Center|Janssen Pharmaceuticals |
Phase 2 |
NCT03289962 |
A Study of RO7198457 (Personalized Cancer Vaccine [PCV]) as a Single Agent and in Combination With Atezolizumab in Participants With Locally Advanced or Metastatic Tumors |
Tumors |
Drug: RO7198457|Drug: Atezolizumab |
Genentech, Inc.|Biontech RNA Pharmaceuticals GmbH |
Phase 1 |
NCT03292588 |
A Trial of Mepolizumab Adjunctive Therapy for the Prevention of Asthma Exacerbations in Urban Children |
Asthma |
Biological: Mepolizumab|Drug: Placebo |
National Institute of
Allergy and Infectious
Diseases (NIAID)
Inner-City Asthma Consortium
GlaxoSmithKline |
Phase 2 |